Press

TransEnterix, Inc. Prices Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–June 11, 2015: TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the pricing of its underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $3.00 per share for total gross proceeds …

Read More

Aegis Surgical Limited Gets FDA Approval of 510(K) Application

RESEARCH TRIANGLE PARK, January 9, 2015: Aegis Surgical Limited, a medical device company focused on a less invasive surgical access system announces the approval by the Food and Drug Administration of its 510(K) submission for the company’s SupraAA Illuminated Mediastinal Access Port. The Aegis Surgical Limited SuprAA System is an illuminated mediastinoscope access port. The Illuminated Mediastinoscope is a trocar/cannula …

Read More

Atrius Limited closes $1 million Series A Preferred Stock Financing

RESEARCH TRIANGLE PARK, August 15, 2014: Atrius Limited, a Synecor spinout company developing a novel, less invasive access system that facilitates percutaneous Transmitral transcatheter mitral valve replacement, announced today that it closed a $1.0 million Series A Preferred Stock financing led by Piedmont Capital Partners, LLC of Greensboro, N.C. Atrius Limited will be managed by William Starling and Richard Stack, …

Read More

TransEnterix to Ring Opening Bell at the New York Stock Exchange

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–July 07, 2014– TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, will ring The Opening Bell(R) of the New York Stock Exchange (NYSE) on Wednesday, July 9, 2014. The company began trading as an NYSE MKT listed company on April 15, …

Read More

Transenterix, Inc. Prices Public Offering of Common Stock

Trading on NYSE MKT to Begin April 15, 2014 RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–April 14, 2014– TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced the pricing of its previously announced underwritten public offering of 12.5 million shares of its common stock at a …

Read More

Abbott Completes Enrollment of Absorb™ Randomized Clinical Trials in the United States, Japan and China

First-of-its-Kind Dissolving Medical Device Being Evaluated in People with Blocked Heart Vessels Comprehensive Clinical Trial Program Demonstrates Abbott’s Global Leadership in Bioresorbable Vascular Scaffold Technology Enrollment Completions Mark Significant Progress Toward Bringing Absorb to Countries Representing More Than 50 Percent of the World’s Heart Stent Market April 10, 2014 Abbott Park, Illinois (NYSE: ABT) — Abbott today announced it has …

Read More

Aegis closes $5.1 million Series A Preferred Stock financing

Aegis Surgical Limited, a Synecor spinout company developing a novel, less invasive access system that facilitates percutaneous Transaortic transcatheter aortic valve replacement, announced today that it closed a $5.1 million Series A Preferred Stock financing led by Piedmont Capital Partners, LLC of Greensboro, N.C.  Aegis Surgical Limited will be managed by William Starling and Richard Stack, MD.

Read More

SafeStitch Medical Completes Merger with TransEnterix

$30 Million Financing Raised from Existing TransEnterix and SafeStitch Medical Stockholders Combined Company to be Renamed TransEnterix IAMI, FL RESEARCH TRIANGLE, N.C.–(BUSINESS WIRE)–SafeStitch Medical, Inc. (OTCBB: SFES) and TransEnterix, Inc., a privately-held company, today announced that they have closed SafeStitch’s previously announced acquisition of TransEnterix. The combined company is expected to be renamed TransEnterix, subject to stockholder approval, and headquartered …

Read More

SafeStitch Medical Announces Definitive Agreement to Merge with TransEnterix

MIAMI, FL and RESEARCH TRIANGLE, N.C., August 14, 2013 – SafeStitch Medical, Inc. (OTCBB: SFES), today announced that it has entered into a definitive agreement to merge with TransEnterix, Inc., a privately-held, medical device company with advanced technology in the use of flexible devices and robotics for minimally invasive surgery. Commenting on the merger, Dr. Jane Hsiao, Chairwoman of SafeStitch …

Read More

Medical device startup raises $13.1 million

By David Ranii — dranii@newsobserver.com edical device startup NeuroTronik, which was spun out of a Chapel Hill business accelerator just 11 months ago, has raised its first round of outside funding: $13.1 million that is earmarked for continued development of a system to treat heart failure. “This has the potential to really be one of the biggest device companies to …

Read More

TransEnterix Secures $55 Million in Financing

“We are pleased with the confidence our distinguished investors have expressed in the TransEnterix team, our technology and the potential it offers for completely changing how laparoscopic surgeries are performed.” Todd M. Pope, President, CEO TransEnterix, Inc. RESEARCH TRIANGLE PARK, N.C. – (October 7, 2009) TransEnterix Inc. has secured $55 million in a second round of institutional financing, paving the …

Read More

TransEnterix’s New Surgical Platform Recognized as ‘Innovation of the Year’ by the Society of Laparoendoscopic Surgeons

“Since TransEnterix’s start, we have collaborated closely with nationally renowned physicians to create a platform that will completely change minimally invasive abdominal surgery as we know it.” Todd M. Pope, President, CEO TransEnterix, Inc. RESEARCH TRIANGLE PARK, N.C. – (September 10, 2009) TransEnterix’s revolutionary laparoscopic surgical platform that allows surgeons to perform minimally invasive abdominal procedures entirely through the umbilicus, …

Read More

TransEnterix Inc Names Experienced Medical Device Executive Todd M. Pope As President, CEO

We believe our company is poised to experience tremendous growth for years to come and I am excited to have the opportunity to lead TransEnterix from its earliest stages.” Todd M. Pope, President, CEO TransEnterix, Inc. RESEARCH TRIANGLE PARK, N.C. (September 24, 2008) TransEnterix, an early-stage, privately-held medical device company focused on advanced minimally invasive surgery, announced today that the …

Read More

Article: Artery, Heal Thyself – Fast Company Magazine – February 2008

Abbott’s new absorbable stent could change heart surgery and revive a $5 billion business. Read the PDF of the full article for more on Synecor’s role in this medical innovation. Full Story (PDF) 

Read More

Synergy Life Science Partners Closes $143M Debut Medical Device Fund

Our goal is to help dramatically improve the standard of patient care in our therapeutic categories, while generating exceptional returns to the customers of and investors in our portfolio companies. John Onopchenko, Managing Director, Synergy Life Science Partners PORTOLA VALLEY, CA (January 8, 2008)…Synergy Life Science Partners, LP, a venture capital limited partnership focused on investments in emerging medical device …

Read More

TransEnterix™ Secures $21 Million in First Round of Institutional Financing

We are pleased to have such high-quality investors involved with us on TransEnterix. With this capital and these investors, we now look forward to the work in delivery of our innovative product platforms. Bill Starling, CEO, Synecor, Interim CEO, TransEnterix RESEARCH TRIANGLE PARK, N.C. (December 31, 2007) Synecor, LLC and SV Life Science Advisers, LLC announce today the first round …

Read More

R. Frederick McCoy, Jr. Appointed As Vice-Chairman Of The Board Of Directors Of Synecor, LLC

Synecor has attracted people and developed methods that are exceptional towards meaningful innovation in medical technology. R. Frederick McCoy, Jr., Vice-Chairman, Synecor Board of Directors RESEARCH TRIANGLE PARK, N.C. (July 17, 2007) Synecor, LLC, a privately held business generator with a history of innovating disruptive medical technologies in immense life science markets for the foundation of new company creation, today …

Read More

InnerPulse™ Secures $50 Million In New Equity Financing

This funding will allow our company the ability to commercialize a technology that will save the lives of many individuals with heart disease. Daniel A. Pelak, President and Chief Executive Officern, InnerPulse, Inc. RESEARCH TRIANGLE PARK, NC (January 29, 2007). . . InnerPulse, Inc, a privately held company developing unique technologies for the treatment of abnormal heart rhythms, announced today …

Read More

Interventional Rhythm Management Changes Name To InnerPulse And Announces A Move To A New Expanded Office, Lab, Manufacturing Facility

We believe our life-saving PICD device is a revolutionary technology that will redefine how we treat patients at risk of Sudden Cardiac Death and save thousands of lives of patients with heart rhythm disorders each year. Daniel A. Pelak, President and Chief Executive Officern, InnerPulse, Inc. RESEARCH TRIANGLE PARK, NC (June 26, 2006). . . InnerPulse, Inc, a privately held …

Read More

Interventional Rhythm Management, Inc. Secures $20 Million in Series B Financing

Research Triangle Park, NC – May 12, 2005 – IRM, Inc., an early stage cardiology company dedicated to the management of patients with cardiac arrhythmias and heart failure, announced today that it has raised $20 Million in Series B Financing. The financing included new investor Johnson & Johnson Development Corporation (JJDC) in addition to previous investors. IRM was founded in …

Read More

BaroSense, Inc. Secures $10 million in Series B Financing

BaroSense is dedicated to providing a safe, effective, and minimally invasive treatment as a new, successful weapon in the battle against obesity. Dan Balbierz, GM & VP of R&D, BaroSense, Inc. David E. Goodman, M.D. Appointed As President And Chief Executive Officer of BaroSense, Inc. Menlo Park, CA – January 31, 2005 – BaroSense Inc., a privately-held medical device company …

Read More

Guidant Completes Acquisition of Bioabsorbable Stent Company

Guidant’s bioabsorbable stent program is aligned with our strategy of leveraging bioabsorbable technologies to provide innovative site-specific therapy for the treatment of heart disease. Dana G. Mead, Jr., President, Vascular Intervention, Guidant Corporation INDIANAPOLIS, Ind. & SANTA CLARA, Calif.–(BUSINESS WIRE)–April 20, 2004–Guidant Corporation (NYSE:GDT – News) today announced the $6 million purchase of the remaining stake in a company developing …

Read More

IRM, Inc., a Synecor LLC Portfolio Company, Raises $15.1 Million in Series A Financing

IRM, Inc. is the synergistic result of our focus on major unmet patient clinical needs, market opportunity, and innovative medical device technology. Richard S. Stack MD, Managing Director of Synecor, LLC Research Triangle Park, NC – December 18, 2003 – IRM, Inc., an early stage cardiology company dedicated to the management of patients with cardiac arrhythmias and heart failure, announced …

Read More

Interventional Rhythm Management, Inc. Announces its Revolutionary Technology Platform for Cardiac Electrophysiology Devices

The IRM IID™ represents a major breakthrough technology for the significantly underserved patient population of defibrillator candidates. Richard S. Stack MD, President, IRM Fundamental Patent Application Published December 4th, 2004. Research Triangle Park, NC – January 12, 2005 – Interventional Rhythm Management Inc. today announces its revolutionary design for cardiac electrophysiology devices, such as implantable defibrillators and pacemakers. IRM’s ground-breaking …

Read More

Guidant Acquires Majority Stake in Bioabsorbable Stent Company

Guidant is enthusiastic about the potential of bioabsorbable stents, which represent a new frontier in the treatment of coronary artery disease. Dana G. Mead, Jr., President, Vascular Intervention, Guidant Corporation INDIANAPOLIS, Apr 1, 2003 (BUSINESS WIRE) — Guidant Corporation (NYSE:GDT), a world leader in the treatment of cardiac and vascular disease, today announced that Guidant will acquire an early-stage company …

Read More
Page 1 of 212»